



ASX RELEASE (9 MAY 2022)

Cleansing Statement

Epsilon Healthcare Limited (ASX:EPN) (Epsilon or the Company) advises that on 3 May 2022, it issued a total of 17,647,059 Fully Paid Ordinary Shares (the Securities) without disclosure to the recipients under Part 6D.2 of the Corporations Act 2001 (Cth) (the Corporations Act).

The Company hereby gives notice under Section 708A(5) of the Corporations Act that:

- (a) The Company has issued the Securities without disclosure to the recipients under Part 6D.2 of the Corporations Act;
 - (b) as at the date of this notice, the Company has complied with the provisions of:
 - a. Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. Section 674 of the Corporations Act; and
 - (c) as at the date of this notice there is no information
 - a. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
 - b. that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
 - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the body; or
 - ii. the rights and liabilities attaching to the relevant securities
- to the extent to which it is reasonable for investors and their professional advisers to expect to find the information in a disclosure document.

ENDS

ASX release authorised by the Joint Company Secretaries.

For further information, please contact:



Jarrold White
Group Chief Executive Officer
e: ceo@epsilonhc.com

Sonny Didugu
Group Chief Operating Officer
e: coo@epsilonhc.com

Steven Xu
Non-Exec Chairman
e: corporate@epsilonhc.com

Investor & Media Enquiries:

Rod Hinchcliffe
Media and Capital Partners
p: +61 412 277 377
e: rod.hinchcliffe@mcpartners.com.au

Melissa Hamilton
Media and Capital Partners
p: +61 417 750 274
e: melissa.hamilton@mcpartners.com.au

Epsilon Healthcare Limited (ASX: EPN) – epsilonhealthcare.com.au

Epsilon Healthcare (ASX:EPN) is a diversified global healthcare and pharmaceuticals company. EPN owns a number of medicinal cannabis assets including the largest GMP cannabis manufacturing facility in the Southern Hemisphere, the Tetra Health clinic group, and the Medimar Platform.